Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07679919 · ClinicalTrials.gov registry record · Phase 1
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies
A Phase 1 study, sponsored by Luminary Therapeutics.
- Not yet
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT07679919 is a Phase 1 study that has not yet begun recruiting, run by Luminary Therapeutics. The registered enrollment target is 27 participants.
The verdict
NCT07679919, a Phase 1 study, has not yet begun recruiting, sponsored by Luminary Therapeutics.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory hematologic malignancies, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractory hematologic malignancies, even after relapse following cluster of differentiation antigen 19 (CD19) targeting CAR-T treatment. This phase 1 study will evaluate safe dose and provide initial signal of the activity of BAFF CAR-T cells against refractory hematologic malignancies using a single lymphodepletion regimen and using a BAFF CAR-T cell manufacturing process.
Interventions
- BIOLOGICAL LMY-922
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2026-09 |
| Est. Completion | 2029-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07679919
The ClinicalTrials.gov registry entry for NCT07679919 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Luminary Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LMY-922 is the first listed.
NCT07679919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07679919 about?
NCT07679919 is a clinical study titled "BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies". Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory hematologic malignancies, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to...
What is the current status of trial NCT07679919?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2026-09. Estimated completion is 2029-04.
What interventions are being tested in trial NCT07679919?
The interventions under investigation include: LMY-922 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07679919?
This trial is sponsored by Luminary Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.